Does the TT Variant of the rs966423 Polymorphism in \textit{DIRC3} Affect the Stage and Clinical Course of Papillary Thyroid Cancer?

Kinga Hinicz\textsuperscript{1,*}, Artur Kowalik\textsuperscript{1}, Iwona Pałyga\textsuperscript{2,3}, Agnieszka Walczyk\textsuperscript{3}, Danuta Gasior-Perczak\textsuperscript{3}, Ester Mikina\textsuperscript{3}, Tomasz Trybek\textsuperscript{3}, Monika Szymonek\textsuperscript{3}, Klaudia Gadowska-Juszczyszyn\textsuperscript{3}, Klaudia Zajkowska\textsuperscript{3}, Agnieszka Suligowska\textsuperscript{5}, Artur Kuchareczko\textsuperscript{3}, Karol Krawczyk\textsuperscript{1}, Janusz Kopczyński\textsuperscript{4}, Magdalena Chrapek\textsuperscript{5}, Stanisław Góźdź\textsuperscript{2,6} and Aldona Kowalska\textsuperscript{2,3}

\textsuperscript{1} Molecular Diagnostics, Holycross Cancer Centre, S. Artwińskiego Str. 3, 25-734 Kielce, Poland; \texttt{arturko@onkol.kielce.pl} (A.K.); \texttt{karol.grzegorz.krawczyk@wp.pl} (K.K.)

\textsuperscript{2} Collegium Medicum, Jan Kochanowski University, IX Wieków Kielc Av. 19, 25-319 Kielce, Poland; \texttt{iwonapa@tlen.pl} (I.P.); \texttt{stanislawgo@onkol.kielce.pl} (S.G.); \texttt{aldonak@onkol.kielce.pl} (A.K.)

\textsuperscript{3} Endocrinology, Holycross Cancer Centre, S. Artwińskiego St. 3, 25-734 Kielce, Poland; \texttt{a.walczyk@post.pl} (A.W.); \texttt{danutagp@o2.pl} (D.G.-P.); \texttt{esterami@tlen.pl} (E.M.); \texttt{trytom1@tlen.pl} (T.T.); \texttt{christ76@interia.pl} (M.S.); \texttt{klaudiagdwsk@op.pl} (K.G.-J.); \texttt{klaudia.ziemianska@gmail.com} (K.Z.); \texttt{a.suligowska@wp.pl} (A.S.); \texttt{arturkuchareczko@gmail.com} (A.K.)

\textsuperscript{4} Surgical Pathology, Holycross Cancer Centre, S. Artwińskiego Str. 3, 25-734 Kielce, Poland; \texttt{januszko@onkol.kielce.pl}

\textsuperscript{5} Department of Probability Theory and Statistics Institute of Mathematics, Faculty of Mathematics and Natural Sciences, Jan Kochanowski University, Świętokerzyska Str. 15, 25-406 Kielce, Poland; \texttt{Magdalena.Chrapek@ujk.edu.pl}

\textsuperscript{6} Clinical Oncology, Holycross Cancer Centre, S. Artwińskiego Str. 3, 25-734 Kielce, Poland

\textsuperscript{*} Correspondence: \texttt{kinga.hin@wp.pl}

Received: 19 January 2020; Accepted: 10 February 2020; Published: 12 February 2020

**Abstract:** Thyroid cancer (TC) is the most common cancer of the endocrine system. Most new diagnoses are of low-grade papillary thyroid cancer (PTC), suggesting that PTC may be overdiagnosed. However, the incidence of advanced-stage PTC has increased in recent years. It is therefore very important to identify prognostic factors for advanced PTC. Somatic mutation of the \textit{BRAF} gene at V600E, or the coexistence of the \textit{BRAF} V600E mutation and mutations in the \textit{TERT} promoter are associated with more aggressive disease. It would also be valuable to identify genetic risk factors affecting PTC prognosis. We therefore evaluated the impact of the rs966423 polymorphism in the \textit{DIRC3} gene, including its relationship with unfavorable histopathological and clinical features and mortality, in differentiated thyroid cancer (DTC). The study included 1466 patients diagnosed with DTC from one center. There was no significant association between the \textit{DIRC3} genotype at rs966423 (CC, CT, or TT) and any histopathological or clinic factor examined, including initial response to therapy, response at follow-up, or overall mortality, in DTC patients.

**Keywords:** papillary thyroid cancer; overdiagnosis; overtreatment; risk factors

---

**1. Introduction**

Thyroid cancer (TC) is the most common cancer of the endocrine system, accounting for 1–2% of all malignancies. The World Health Organization reported 567,233 new cases of TC in 2018, of which 130,889 occurred in men and 436,344 occurred in women [1]. Recent years have seen a very sharp rise in incidence of differentiated thyroid cancer (DTC), mainly low-grade papillary thyroid
Cancers 2020, 12, 423

The increase in the diagnosis of PTC is thought to result from better availability of diagnostic imaging and the frequent use of fine needle aspiration biopsies. Moreover, the proportion of microcarcinomas found during cancer surgery increased from 18.4% in 1983–1987 to 43.1% in 1998–2001 [2]. Autopsy studies show that papillary thyroid microcarcinoma was found in up to 35.6% of people who died from other causes [3,4]. PTC is a relatively benign tumor, in which the 10-year survival rate is approximately 95% [5]. Therefore, it is possible that PTC is over-diagnosed and overtreated [5,6]. However, a study of the Surveillance, Epidemiology, and End Results (SEER) dataset examining 77,276 patients with TC from 1974–2013 identified an increase in the incidence of advanced-stage PTC [7]. The main risk factors that have led to this worldwide increase in TC are obesity, smoking, iodine intake, and environmental risk factors such as exposure to radiation, flame retardants, or volcanic ash [8]. The overall mortality of TC varies over time. According to a study of the SEER-9 data, the overall incidence of thyroid cancer rose by 3.6% per year between 1974 and 2013, and incidence-based mortality increased by 1.1%. Overall mortality increased from 0.40 per 100,000 person-years in 1994–1997 to 0.46 per 100,000 person-years in 2010–2013 [7,8]. At the same time, there are patients in whom the course of the cancer is rapid, and early identification of these patients is extremely important for treatment efficacy. So far, a more severe disease course has been associated with unfavorable histopathologic features, the presence of the V600E somatic mutation of the \textit{BRAF} gene, and the coexistence of the \textit{BRAF} V600E mutation with mutations in the \textit{TERT} promoter [9,10]. However, all these factors can be identified only after surgical intervention, which makes it challenging to properly plan and adapt the treatment to the needs of a particular patient. It would be very attractive if germline genetic risk factors could be identified, which would allow physicians to estimate the prognosis of the patient before surgery. In contrast to somatic changes, which can only be identified in surgically obtained tumor samples, germline variants can be identified in the peripheral blood of the patient. Research carried out to date identified a few genes associated with vulnerability to the development of DTC, including \textit{DICER1}, \textit{FOXE1}, \textit{PTCSC2}, \textit{MYH9}, \textit{SRGAP1}, \textit{HABP2}, \textit{BRCA1}, \textit{CHEK2}, \textit{ATM}, \textit{RASAL1}, \textit{SRRM2}, \textit{XRCC1}, \textit{TITF-1/NKX2.1}, and \textit{PTCSC3} [11–22]. Recently, seven chromosomal loci (1p13.2–1q21, 1q21, 2q21, 6q22, 8p23.1–p22, 8q24, and 19p13.2) associated with DTC development were identified [18]. Genome-wide association studies (GWAS) identified genetic variants as candidate germline risk factors in Japanese, Chinese, Polish, and British populations [23]. In the literature, there are a few reports demonstrating the prognostic significance of the rs966423 polymorphism in the \textit{DIRC3} (disrupted in renal carcinoma 3) gene, and its relationship with unfavorable histopathologic features and mortality in patients diagnosed with DTC. The rs966423 polymorphism is located at the 2q35 locus of \textit{DIRC3}, within a long non-coding RNA (lncRNA). \textit{DIRC3} was first identified in 2003 as a fusion transcript involved in familial renal carcinoma [24]. Due to the ambiguous role of the rs966423 polymorphism in \textit{DIRC3} as a prognostic factor in PTC, we assessed the correlation between this variant and the clinical course of TC.

2. Materials and Methods

2.1. Patients and Controls

All study procedures were approved by the Institutional Review Board of the Holycross Chamber of Physicians in Kielce, Poland. Living patients provided signed consent for molecular tests to be carried out. The study included 1466 patients (1445 alive patients and 21 dead patients, where types of TC were following: 1386 PTC cases, 42 poorly differentiated thyroid carcinoma (PDTC) cases, 34 follicular thyroid carcinoma (FTC) cases, and 4 oxyphilic TC cases) diagnosed between 2000 and 2018 at the Holycross Cancer Center (HCC) in Kielce and patients who were diagnosed with PTC in 2000–2018 but whose monitoring was stopped due to death. A group of 309 healthy individuals was included in the study as a control cohort. All cases and controls were recruited at the HCC in Kielce. Peripheral blood was taken, and archived blocks of primary tumor tissue were obtained. Patients who failed to provide signed consent for molecular testing or who were lost to follow-up for reasons other than patient death were excluded. Retrospective clinical data were available for all of the cases. Demographic and clinical data, including patient gender, age at diagnosis of TC, tumor size,
multifocality, extrathyroidal extension, vascular invasion, lymph node, distant metastasis, clinical stage, response to primary treatment, clinical course, and final disease status were obtained from medical records. All cases were restaged according to the recently updated 8th Edition of the American Joint Committee on Cancer (AJCC) tumor node metastasis (TNM) Staging System.

2.2. DNA Isolation from Blood Samples

Genomic DNA isolated from whole peripheral blood was used for genetic analyses. Material was isolated using the Maxwell RSC Blood DNA Kit (Promega, Madison, WI, USA), according to the manufacturer’s instructions. DNA quality and purity were verified using a NanoDrop spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA).

2.3. DNA Isolation from FFPE Samples

A pathologist marked the area without tumor cells on hematoxylin and eosin-stained slides. The pathologist-selected areas from unstained slides were used for DNA extraction using the Maxwell 16 FFPE Tissue LEV DNA Purification Kit, according to the manufacturer’s instructions (Promega). DNA quality and purity were verified on a NanoDrop spectrophotometer (Thermo Fisher Scientific).

2.4. Quantitative Polymerase Chain Reaction (qPCR) and Sanger Sequencing

Detection of DIRC3 genetic variants was performed by quantitative polymerase chain reaction (qPCR) using the TaqMan SNP Genotyping Assay kit (Thermo Fisher Scientific) and sequencing of PCR products. The region of DIRC3 containing the polymorphism was amplified using the following oligonucleotide primer pair: forward, 5'-CAGCCTTTCATCCAGGAAACAG-3' and reverse, 5'-TCCACTGGGCTCTCAACTACAATCTG-3'. The amplification conditions consisted of an initial denaturation at 95 °C for 15 min and then 39 cycles of denaturation at 95 °C for 15 s, annealing at 61 °C for 15 s, and extension at 72 °C for 15 s, followed by a final extension at 72 °C for 2 min. PCR was performed using a Veriti Thermal Cycler (Applied Biosystems, Foster City, CA, USA). PCR products were separated by microchip electrophoresis using the MultiNA System (Shimadzu Corporation, SHIM-POL, Poland). Amplified PCR products were purified using FastAP and Exonuclease I (Thermo Fisher Scientific). After purification of the resulting PCR products, sequencing was performed using the BigDye Terminator v1.1 Cycle Sequencing kit (Life Technologies/Thermo Fisher Scientific), and the same forward and reverse primers. The primers were diluted at a ratio of 8:42 μL in water, and PCR products were separated and analyzed on an ABI 3130 Automatic Capillary DNA Sequencer (Applied Biosystems).

2.5. Statistical Analysis

Quantitative data are described by means, standard deviations, medians, quartiles, and ranges (minimum and maximum). Categorical data were described by frequencies and percentages. Group comparisons were performed using chi-squared or Fisher’s exact tests for categorical variables; t-tests for quantitative, normally distributed variables; or Mann–Whitney tests for quantitative, non-normally distributed variables. The normality of distribution was determined by Shapiro–Wilk tests. Statistical tests were two-tailed, and p-values < 0.05 were considered significant. All statistical analyses were performed using the R software package, version 3.6.1., The R Foundation for Statistical Computing, Vienna, Austria.

3. Results

3.1. Characteristics at Presentation and Primary Treatment

Patient demographics and the clinicopathological features of all 1466 cases are presented in (Table 1, S1). There were 1269 women (86.6%, 1269/1466) and 197 men (13.4%, 197/1466) in the study group. The study group included patients with the four most common types of TC: 1386 PTC cases (94.5%), 34 FTC cases (2.3%), 42 PDTC cases (2.9%), and four oxyphilic cases (0.3%). The dominant
histological variant was classic for PTC (71.2%), minimally invasive for FTC (85.3%), and insular for PDTC (69%). The median age at diagnosis was 51 years (range, 15–85), and most patients (61.8%) were < 55 years old. The median tumor size was 9 mm (range, 0.0–130). Most patients (74.2%, 1088/1466) did not have tumor multifocality. Gross type extrathyroidal extension was detected in 1.6% patients (23/1466). Angioinvasion was present in 6.8% (99/1466) of patients. Lymph node metastases and distant metastases were present in 14.8% (218/1466) and 2.3% (34/1466) of patients, respectively. An advanced TNM stage of III or IV, according to the updated 8th Edition of the AJCC TNM staging system, was observed in 26 patients (1.8%, 26/1466). According to the American Thyroid Association (ATA) initial risk criteria, 959 (65.4%) patients were classified as low risk (LR), 416 (28.4%) as intermediate risk (IR), and 91 (6.2%) as high risk (HR).

Table 1. Characteristics of the study group.

| Feature                          | Total (n = 1466) |
|----------------------------------|-----------------|
| **Gender, n (%)**                |                 |
| Female                           | 1269 (86.6%)    |
| Male                             | 197 (13.4%)     |
| **Median age, years (Q1–Q3; range)** | 51.0 (39.0–59.8; 15–85) |
| **Age at diagnosis, ≥ 55 years, n (%)** | 560 (38.2%)     |
| **Median tumor size, mm (Q1–Q3; range)** | 9.0 (5.0–16.0; 0.0–130) |
| **TC main type, n (%)**          |                 |
| FTC                              | 34 (2.3%)       |
| Oxyphilic                        | 4 (0.3%)        |
| PDTC                             | 42 (2.9%)       |
| PTC                              | 1386 (94.5%)    |
| **Multifocality, n (%)**         |                 |
| No                               | 1088 (74.2%)    |
| Yes                              | 378 (25.8%)     |
| **Extrathyroidal extension, n (%)** |                 |
| No                               | 1176 (80.2%)    |
| Minor                            | 267 (18.2%)     |
| Gross                            | 23 (1.6%)       |
| **Angioinvasion, n (%)**         |                 |
| No                               | 1367 (93.2%)    |
| Yes                              | 99 (6.8%)       |
| **Tumor stage, n (%)**           |                 |
| pT0                              | 2 (0.1%)        |
| pT1a                             | 859 (58.6%)     |
| pT1b                             | 333 (22.7%)     |
| pT2                              | 168 (11.5%)     |
| pT3a                             | 77 (5.3%)       |
| pT3b                             | 11 (0.8%)       |
| pT4a                             | 12 (0.8%)       |
| pT4b                             | 4 (0.3%)        |
| **Node stage, n (%)**            |                 |
| N0a                              | 770 (52.5%)     |
| N0b                              | 478 (32.6%)     |
| N1a                              | 150 (10.2%)     |
| N1b                              | 68 (4.6%)       |
| **Distant metastasis, n (%)**    |                 |
| M0                               | 1432 (97.7%)    |
| M1                               | 34 (2.3%)       |
| **TNM stage, n (%)**             |                 |
| I                                | 1342 (91.5%)    |
| II                               | 98 (6.7%)       |
| III                              | 4 (0.3%)        |
| IVa                              | 3 (0.2%)        |
3.2. Response to Therapy and Follow-up

The initial response to therapy was evaluated for 12 months at our center. The types of responses were classified into 4 groups: excellent, indeterminate, biochemical incomplete, and structural incomplete according to the criteria in the ATA recommendations [25]. Out of 1466 patients, 1343 were assessed. For 123 patients, no initial response to therapy was available because the course of treatment was too short. An excellent response to primary therapy was observed in 1116 patients (83.1%), while in 160 patients (11.9%) the response was indeterminate. A biochemical incomplete response to initial therapy was observed in 32 patients (2.4%), while a structural incomplete response was observed in 35 patients (2.6%). Recurrence after an excellent response to initial therapy occurred in ten patients (0.7%). Recurrence was defined as the appearance of disease after no evidence of disease (NED). At the end of the study, NED was observed in 1226 patients (91.3%). Of the remaining patients, 69 (5.2%) had an indeterminate response and 47 patients (3.5%) exhibited biochemically or structurally persistent disease. There were three deaths among cases with the classic variant of PTC, four deaths among cases with the solid variant of PDTC, 13 deaths among cases with the insular variant of PDTC, and one death among cases with the oxyphilic type of TC. The median follow-up time of the study group was 60 months (range: 24–132 months) (Table 2, S2).

Table 2. Initial response to therapy and response at follow-up in the study group.

| Initial Response to Therapy | n (%) |
|----------------------------|-------|
| Excellent                  | 1116 (83.1%) |
| Indeterminate              | 160 (11.9%)  |
| Biochemical incomplete     | 32 (2.4%)   |
| Structural incomplete      | 35 (2.6%)   |

| Final Follow-Up | n (%) |
|-----------------|-------|
| NED             | 1226 (91.3%) |
| Indeterminate   | 69 (5.2%)    |
| Biochemical incomplete | 14 (1.1%)   |
| Structural incomplete | 33 (2.4%)   |

| Follow-Up: Recurrence after NED | n (%) |
|---------------------------------|-------|
| No                              | 1106 (82.3%) |
| Yes                             | 10 (0.7%)   |

| Death | n (%) |
|-------|-------|
| No    | 1445 (98.6%) |
| TC-unrelated | 6 (0.4%) |
| TC-related   | 15 (1.0%)   |

| Median Follow-Up Time, Years (Range) | 5.0 (0.0–40.0) |

NED, no evidence of disease; TC, thyroid cancer.
3.3. Relationship between rs966423 Genotype and Histopathologic Factors and Response

The frequencies of the rs966423 genotypes (CC, CT, and TT) in the study group were 22% (322/1466), 49.8% (730/1466), and 28.2% (414/1466), respectively. In the control group, 17.5% (54/309) of patients were CC carriers, 50.2% (155/309) were CT carriers, and 32.4% (100/309) were TT carriers (Table 3). Statistical analysis revealed no significant difference in the frequencies of DIRC3 variants between the study group and the control group (Fisher’s exact test, \( p = 0.140 \)). In addition, statistical analysis indicated no significant difference in the ratio of TT carriers versus CC or CT carriers in patients with TC compared with the control group (Fisher’s exact test, \( p = 0.147 \)). We also assessed the relationships between polymorphisms in DIRC3 (CC, CT, or TT) and clinical factors, including initial response to therapy, response at follow-up, and overall mortality. No statistically significant differences were found (Table 4). In addition, statistical analysis in ATA initial risk sub-groups indicated no significant difference in association the frequencies of the TT carriers and high ATA initial risk (Table S3–S5). However the highest risk of recurrence is observed in the first 5 years of follow-up [26], we did not find a significant association of the frequencies of recurrence or death in the TT carriers in analysis of 538 patients with longer follow-up (the median follow-up time: 13 years) (Table S6).

Table 3. Frequency of rs966423 variants among the study and control groups.

| rs966423 Variants | Study Group \( n = 1466 \), \( n \) (%) | Controls \( n = 309 \), \( n \) (%) | \( p \)-Value |
|-------------------|--------------------------------------|----------------------------------|-------------|
| CC                | 322 (22.0%)                          | 54 (17.5%)                       |             |
| CT                | 730 (49.8%)                          | 155 (50.2%)                      |             |
| TT                | 414 (28.2%)                          | 100 (32.4%)                      | \( p = 0.140 \) |
| CC/CT             | 1144 (78.0%)                         | 255 (82.5%)                      |             |
| TT/CC             | 1052 (71.8%)                         | 209 (67.6%)                      | \( p = 0.147 \) |

Table 4. Relationships between rs966423 variants and histopathological and clinical factors.

| Feature                          | TT \( n = 414 \) | CC/CT \( n = 1052 \) | Total \( n = 1466 \) | \( p \)-Value |
|----------------------------------|-----------------|----------------------|---------------------|--------------|
| Gender, \( n \) (%)              |                 |                      |                     |              |
| Female                           | 366 (88.4%)     | 903 (85.8%)          | 1269 (86.6%)        |              |
| Male                             | 48 (11.6%)      | 149 (14.2%)          | 197 (13.4%)         | 0.1941       |
| Median age at diagnosis, years   |                 |                      |                     | 0.836        |
| (Q1–Q3; range)                   | 51.0 (40.0–60.0; 15.0–85.0) | 51.0 (39.0–59.0; 15–85) | 51.0 (39.0–59.8; 15–85) |              |
| Age at diagnosis, \( \geq 55 \) years, \( n \) (%) | 162 (39.1%) | 398 (37.8%) | 560 (38.2%) | 0.6453      |
| Median tumor size, mm (Q1–Q3; range) | 9.0 (6.0–17.8; 0.0–80.0) | 9.0 (5.0–15.0; 0.0–130) | 9.0 (5.0–16.0; 0.0–130) | 0.126        |
| TC main type, \( n \) (%)        |                 |                      |                     |              |
| FTC                             | 14 (3.4%)       | 20 (1.9%)            | 34 (2.3%)           |              |
| Oxyphilic                       | 2 (0.5%)        | 2 (0.2%)             | 4 (0.3%)            |              |
| PDTC                            | 12 (2.9%)       | 30 (2.9%)            | 42 (2.9%)           |              |
| PTC                             | 386 (93.2%)     | 1000 (95.1%)         | 1386 (94.5%)        | 0.2411       |
| Multifocality, n (%) | No | 315 (76.1%) | 773 (73.5%) | 1088 (74.2%) |
|---------------------|----|-------------|-------------|-------------|
|                     | Yes| 99 (23.9%)  | 279 (26.5%) | 378 (25.8%) |
|                     |    | 0.3042      |             |             |

| Extrathyroidal extension, n (%) | No | 333 (80.4%) | 843 (80.1%) | 1176 (80.2%) |
|---------------------------------|----|-------------|-------------|-------------|
|                                 | Yes| 73 (17.6%)  | 194 (18.4%) | 267 (18.2%) |
|                                 |    | 0.7424      |             |             |

| Angioinvasion, n (%) | No | 381 (92.0%) | 986 (93.7%) | 1367 (93.2%) |
|---------------------|----|-------------|-------------|-------------|
|                     | Yes| 33 (8.0%)   | 66 (6.3%)   | 99 (6.8%)   |
|                     |    | 0.2437      |             |             |

| Tumor stage, n (%) | pT0 | 1 (0.2%) | 1 (0.1%) | 2 (0.1%) |
|--------------------|-----|---------|---------|---------|
|                    | pT1a| 227 (54.8%) | 632 (60.1%) | 859 (58.6%) |
|                    | pT1b| 102 (24.6%) | 231 (22.0%) | 333 (22.7%) |
|                    | pT2 | 50 (12.1%) | 118 (11.2%) | 168 (11.5%) |
|                    | pT3a| 23 (5.6%) | 54 (5.1%) | 77 (5.3%) |
|                    | pT3b| 5 (1.2%) | 6 (0.6%) | 11 (0.8%) |
|                    | pT4a| 5 (1.2%) | 7 (0.7%) | 12 (0.8%) |
|                    | pT4b| 1 (0.2%) | 3 (0.3%) | 4 (0.3%) |
|                    |    | 0.4434      |             |             |

| Node stage, n (%) | N0a | 208 (50.2%) | 562 (53.4%) | 770 (52.5%) |
|-------------------|-----|-------------|-------------|-------------|
|                   | N0b | 134 (32.4%) | 344 (32.7%) | 478 (32.6%) |
|                   | N1a | 48 (11.6%) | 102 (9.7%) | 150 (10.2%) |
|                   | N1b | 24 (5.8%) | 44 (4.2%) | 68 (4.6%) |
|                   |    | 0.3479      |             |             |

| Distant metastasis, n (%) | M0 | 402 (97.1%) | 1030 (97.9%) | 1432 (97.7%) |
|---------------------------|----|-------------|-------------|-------------|
|                           | M1 | 12 (2.9%)   | 22 (2.1%)   | 34 (2.3%)   |
|                           |    | 0.3552      |             |             |

| 8th edition of TNM staging, n (%) | I  | 375 (90.6%) | 967 (91.9%) | 1342 (91.5%) |
|-----------------------------------|----|-------------|-------------|-------------|
|                                   | II | 31 (7.5%)  | 67 (6.4%) | 98 (6.7%) |
|                                   | III| 2 (0.5%)   | 2 (0.2%) | 4 (0.3%) |
|                                   | Iva| 1 (0.2%)   | 2 (0.2%) | 3 (0.2%) |
|                                   | Ivb| 5 (1.2%)   | 14 (1.3%) | 19 (1.3%) |
|                                   |    | 0.7103      |             |             |

| ATA initial risk, n (%) | Low | 264 (63.8%) | 695 (66.1%) | 959 (65.4%) |
|-------------------------|-----|-------------|-------------|-------------|
|                         | Inter | 118 (28.5%) | 298 (28.3%) | 416 (28.4%) |
|                         | High  | 32 (7.7%) | 59 (5.6%) | 91 (6.2%) |
|                         |    | 0.3018      |             |             |
Response to initial therapy, \( n \) (%)

| Response Type         | Group 1   | Group 2   | Group 3   |
|-----------------------|-----------|-----------|-----------|
| Excellent             | 319 (83.5%) | 797 (82.8%) | 1116 (83.1%) |
| Indeterminate         | 45 (11.8%)  | 115 (12%)  | 160 (11.9%)  |
| Biochemical incomplete| 9 (2.4%)   | 23 (2.4%)  | 32 (2.4%)   |
| Structural incomplete | 8 (2.1%)   | 27 (2.8%)  | 35 (2.6%)   | 0.9528

Final follow-up, \( n \) (%)

| Status     | Group 1       | Group 2       | Group 3       |
|------------|---------------|---------------|---------------|
| NED        | 346 (91.1%)   | 880 (91.5%)   | 1226 (91.3%)  |
| Indeterminate | 25 (6.6%) | 44 (4.6%) | 69 (5.1%) |
| Biochemical incomplete | 4 (1.1%) | 10 (1.0%) | 14 (1.1%) |
| Structural incomplete | 5 (1.2%) | 28 (2.9%) | 33 (2.5%) | 0.280

Follow-up: recurrence after NED, \( n \) (%)

| Recurrence | Group 1       | Group 2       | Group 3       |
|------------|---------------|---------------|---------------|
| No         | 317 (99.4%)   | 789 (99%)     | 1106 (99.1%)  |
| Yes        | 2 (0.6%)      | 8 (1.0%)      | 10 (0.9%)     | 0.7852

Death, \( n \) (%)

| Status       | Group 1       | Group 2       | Group 3       |
|--------------|---------------|---------------|---------------|
| No           | 408 (98.6%)   | 1037 (98.6%)  | 1445 (98.6%)  |
| TC-unrelated | 3 (0.7%)      | 3 (0.3%)      | 6 (0.4%)      |
| TC-related   | 3 (0.7%)      | 12 (1.1%)     | 15 (1.0%)     | 0.9729

Median follow-up time, years (range)

| Time (range) | Group 1       | Group 2       | Group 3       |
|--------------|---------------|---------------|---------------|
| 5.0 (0.0–27.0) | 5.0 (0.0–40.0) | 5.0 (0.0–40.0) | 0.360

TC, thyroid cancer; FTC, follicular thyroid carcinoma; PDTC, poorly differentiated thyroid carcinoma; PTC, papillary thyroid carcinoma; ATA, American Thyroid Association; TNM, tumor node metastasis; NED, no evidence of disease.

4. Discussion

Genetic prognostic factors in DTC are still poorly understood, but increasing evidence suggests that multiple low-penetrance genetic variants, rather than a few high-penetrance variants, can better explain the risk of DTC [27]. A GWAS of European populations identified five low-penetrance variants potentially involved in DTC risk, including rs965513 on 9q22, rs944289 on 14q13, rs966423 on 2q35, rs2439302 on 8p12, and rs116909374 on 14q13.3 [28,29]. The rs966423 polymorphism is located at 2q35 of the \( DIRC3 \) gene, within a lncRNA. \( DIRC3 \) was first identified in 2003 as a fusion transcript involved in familial renal carcinoma [24]. Although the function of \( DIRC3 \) is unknown, it is thought to have tumor suppressor activity. In a GWAS, \( DIRC3 \) variants were associated both with TC risk and thyroid stimulating hormone levels. It is thus possible that genetic variants in \( DIRC3 \) alter thyroid stimulating hormone production, and therefore indirectly promote TC development as a result of decreased thyroid epithelium differentiation [28]. Recently, Świerniak et al. published the results of a study indicating a relationship between the TT variant of the rs966423 polymorphism, and a worse prognosis and increased overall mortality in patients with DTC [30]. Świerniak et al. detected the TT genotype in 518/1836 patients (28%) in their cohort, but the study did not include a control group. We detected the TT genotype in 414/1466 DTC patients (28.2%) and 100/303 healthy
individuals (32.4%) in the control cohort. Statistical analysis indicated no significant difference in the incidence of the TT variant between the DTC patients and the control population (Fisher’s exact test, \( p = 0.140 \)). Similar data was published by Wang et al., where the TT genotype was detected in 2.7% of PTC patients and 4.3% of controls, although this study was conducted in a Chinese population. [31] These observations are inconsistent with the idea that the TT variant of rs966423 is a risk factor for the development of DTC. In addition, we assessed the correlation between \textit{DIRC3} genotype (CC, CT, or TT) and histopathological and clinical features, including initial response to therapy, response at follow-up, and overall mortality, in patients with DTC. The analysis did not reveal any statistically significant differences (Table 4, S2). By contrast, Świerniak et al. reported that the TT variant did significantly correlate with conventional risk factors, including lymph node metastasis, extrathyroidal invasion, angioinvasion, and stage IV disease, as well as increased overall mortality, in patients with TC. However, the difference in risk was only significant when comparing the TT variant carriers with carriers of the CC and CT genotypes combined. According to Ensembl (https://www.ensembl.org/), the TT variant is present in 31.8% of Europeans overall (Finnish, 25.3%; British, 33%; Iberian, 36.4%; and Toscani, 38.3%), indicating a high frequency in this populations. Moreover, the TT genotype is more common than the ancestral genotype (CC) [32].

5. Conclusions

In conclusion, based on our results, the TT variant of the rs966423 polymorphism in the \textit{DIRC3} gene is not associated with a higher risk of developing DTC, a worse prognosis, or increased overall mortality in patients with DTC in a Polish population. To verify the influence of the TT variant on survival in DTC patients, it may be necessary to perform multi-ethnic studies with larger numbers of patients and controls.

Supplementary Materials: The following are available online at www.mdpi.com/xxx/s1, Table S1: Characteristics of the study group, Table S2: Relationship between rs966423 and histoclinic factors, response to therapy, follow-up, and overall mortality, Table S3: Relationship between rs966423 and ATA low-risk, Table S4: Relationship between rs966423 and ATA intermediate-risk, Table S5: Relationship between rs966423 and ATA high-risk, Table S6: Relationship between rs966423 and histoclinic factors, response to therapy, follow-up, and overall mortality for patients with longer follow-up.

Author Contributions: Conceptualization, K.H. and A.K. (Aldona Kowalska); Methodology, K.H.; Software, M.C.; Validation, K.H., A.K. (Aldona Kowalska) and A.K. (Artur Kowalik); Formal analysis, K.H.; Investigation, K.H.; Data curation, K.H; Writing—original draft preparation, K.H.; Writing—review and editing, K.H., A.K. (Aldona Kowalska), A.K. (Artur Kowalik), I.P., D.G.-P, A.W., E.M., T.T., M.S., K.G.-J., K.Z., A.K. (Artur Kuchareczko), A.S., K.K., J.K., S.G.; supervision, K.H. All authors have read and agreed to the published version of the manuscript.

Funding: Project financed under the program of the Minister of Science and Higher Education called “Regional Initiative of Excellence” in the years, project no 024/RID/2018/19, amount of financing 11 999 000,00 zł.

Conflicts of Interest: The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

References

1. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries-Bray-2018-CA: A Cancer Journal for Clinicians-Wiley Online Library. Available online: https://onlinelibrary.wiley.com/doi/full/10.3322/caac.21492 (accessed on 11 October 2019).
2. Leenhardt, L.; Grosclaude, P.; Chérié-Challine, L.; Thyroid Cancer Committee Increased incidence of thyroid carcinoma in france: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee. \textit{Thyroid} \textbf{2004}, \textit{14}, 1056–1060.).
3. Prevalence of Differentiated Thyroid Cancer in Autopsy Studies over Six Decades: A Meta-Analysis-PubMed-NCBI. Available online: https://www.ncbi.nlm.nih.gov/pubmed/27601555 (accessed on 19 December 2019).
4. Rosai, J.; LiVolsi, V.A.; Sobrinho-Simoes, M.; Williams, E.D. Renaming papillary microcarcinoma of the thyroid gland: The Porto proposal. \textit{Int. J. Surg. Pathol.} \textbf{2003}, \textit{11}, 249–251.
5. Mazzaferri, E.L.; Jhiang, S.M. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am. J. Med. 1994, 97, 418–428.
6. Jegerlehner, S.; Bulliard, J.-L.; Aujesky, D.; Rodondi, N.; Germann, S.; Konzelmann, I.; Chiolero, A. Overdiagnosis and overtreatment of thyroid cancer: A population-based temporal trend study. PLoS One 2017, 12..
7. Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974–2013-PubMed-NCBI. Available online: https://www.ncbi.nlm.nih.gov/pubmed/28362912 (accessed on 11 October 11 2019).
8. Geographic Influences in the Global Rise of Thyroid Cancer Nature Reviews Endocrinology. Available online: https://www.nature.com/articles/s41574-019-0263-x (accessed on 19 December 2019).
9. Response to Therapy of Papillary Thyroid Cancer of Known BRAF Status-Kowalska-2017-Clinical Endocrinology-Wiley Online Library. Available online: https://onlinelibrary.wiley.com/doi/abs/10.1111/cen.13423 (accessed on 11 October 2019).
10. Impact of BRAF V600E and TERT Promoter Mutations on Response to Therapy in Papillary Thyroid Cancer. PubMed-NCBI. Available online: https://www.ncbi.nlm.nih.gov/pubmed/31035897 (accessed on 11 October 2019).
11. Rutter, M.M.; Jha, P.; Schultz, K.A.P.; Sheil, A.; Harris, A.K.; Bauer, A.J.; Field, A.L.; Geller, J.; Hill, D.A. DICER1 Mutations and Differentiated Thyroid Cancer: Evidence of a Direct Association. J. Clin. Endocrinol. Metab. 2016, 101, 1–5.
12. Pereira, J.S.; da Silva, J.G.; Tomaz, R.A.; Pinto, A.E.; Bugalho, M.J.; Leite, V.; Cavaco, B.M. Identification of a novel germline FOXE1 variant in patients with familial non-medullary thyroid carcinoma (FNMTC). Endocrine 2015, 49, 204–214.
13. He, H.; Bronisz, A.; Liyanarachchi, S.; Nagy, R.; Li, W.; Huang, Y.; Akagi, K.; Saji, M.; Kula, D.; Wojcicka, A.; et al. SRGAP1 is a candidate gene for papillary thyroid carcinoma susceptibility. J. Clin. Endocrinol. Metab. 2013, 98, E973–E980.
14. Gara, S.K.; Jia, L.; Merino, M.J.; Agarwal, S.K.; Zhang, L.; Cam, M.; Patel, D.; Kebebew, E. Germline HABP2 Mutation Causing Familial Nonmedullary Thyroid Cancer. N. Engl. J. Med. 2015, 373, 448–455.
15. Wójcicka, A.; Czetwertyńska, M.; Święmięcińska, M.; Długosieńska, J.; Maciąg, M.; Czajka, A.; Dymecka, K.; Kubiak, A.; Kot, A.; Płoski, R.; et al. Variants in the ATM-CHEK2-BRCA1 axis determine genetic predisposition and clinical presentation of papillary thyroid carcinoma. Genes Chromosomes Cancer 2020, 53, 516–523.
16. Siolek, M.; Cybulski, C.; Gaśior-Perczak, D.; Kowalik, A.; Kozak-Klonowska, B.; Kowalska, A.; Chlopek, M.; Kluźniak, W.; Wokolorczyk, D.; Paliyga, I.; et al. CHEK2 mutations and the risk of papillary thyroid cancer. Int. J. Cancer 2015, 137, 548–552.
17. Dombernowsky, S.L.; Weischer, M.; Allin, K.H.; Bojesen, S.E.; Tybjerg-Hansen, A.; Nordestgaard, B.G. Risk of Cancer by ATM Missense Mutations in the General Population. JCO 2008, 26, 3057–3062.
18. Peiling Yang, S.; Ngew, J. Familial non-medullary thyroid cancer: Unraveling the genetic maze. Endocr. Relat. Cancer 2016, 23, R577–R595.
19. A germline Mutation in SRRM2, A Splicing Factor Gene is Implicated in Papillary Thyroid Carcinoma Predisposition-Semantic Scholar. Available online: https://www.semanticscholar.org/paper/A-germline-mutation-in-SRRM2%2C-a-splicing-factor-is-Tomsic-He/497dc1da6155e4d729e5a8c77f9d5863a676fb2a (accessed on 2 June 2019).
20. XRCC1 Polymorphisms and Risk of Papillary Thyroid Carcinoma in a Korean Sample. PubMed-NCBI. Available online: https://www.ncbi.nlm.nih.gov/pubmed/21860547 (accessed on 2 June 2019).
21. Ngan, E.S.W.; Lang, B.H.H.; Liu, T.; Shum, C.K.Y.; So, M.-T.; Lau, D.K.C.; Leon, T.Y.Y.; Cherny, S.S.; Tsai, S.Y.; Lo, C.-Y.; et al. A germline mutation (A339V) in thyroid transcription factor-1 (TITF-1/NKX2.1) in patients with multinodular goiter and papillary thyroid carcinoma. J. Natl. Cancer Inst. 2009, 101, 162–175.
22. Jendrzejewski, J.; He, H.; Radomska, H.S.; Li, W.; Tomsic, J.; Liyanarachchi, S.; Davuluri, R.V.; Nagy, R.; de la Chapelle, A. The polymorphism rs944289 predisposes to papillary thyroid carcinoma through a large intergenic noncoding RNA gene of tumor suppressor type. Proc. Natl. Acad. Sci. USA 2012, 109, 8646–8651.
23. Saenko, V.A.; Rogounovitch, T.I. Genetic Polymorphism Predisposing to Differentiated Thyroid Cancer: A Review of Major Findings of the Genome-Wide Association Studies. Endocrinol. Metab. 2018, 33, 164–174.
24. Bodmer, D.; Schepens, M.; Eleveld, M.J.; Schoenmakers, E.F.P.M.; Geurts van Kessel, A. Disruption of a novel gene, DIRC3, and expression of DIRC3-HSPBAP1 fusion transcripts in a case of familial renal cell cancer and t (2; 3) (q35; q21). Genes Chromosomes Cancer 2003, 38, 107–116.
25. Haugen, B.R.; Alexander, E.K.; Bible, K.C.; Doherty, G.M.; Mandel, S.J.; Nikiforov, Y.E.; Pacini, F.; Randolph, G.W.; Sawka, A.M.; Schlumberger, M.; et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. *Thyroid* 2016, 26, 1–133.

26. Durante, C.; Montesano, T.; Torlontano, M.; Attard, M.; Monzani, F.; Tumino, S.; Costante, G.; Meringolo, D.; Bruno, R.; Trulli, F.; et al. Papillary thyroid cancer: Time course of recurrences during postsurgery surveillance. *J. Clin. Endocrinol. Metab.* 2013, 98, 636–642.

27. Landa, I.; Robledo, M. Association studies in thyroid cancer susceptibility: Are we on the right track? *J. Mol. Endocrinol.* 2011, 47, R43–R58.

28. Gudmundsson, J.; Sulem, P.; Gudbjartsson, D.F.; Jonasson, J.G.; Masson, G.; He, H.; Jonasdottir, A.; Sigurdsson, A.; Stacey, S.N.; Johannsdottir, H.; et al. Discovery of common variants associated with low TSH levels and thyroid cancer risk. *Nat. Genet.* 2012, 44, 319–322.

29. Gudmundsson, J.; Sulem, P.; Gudbjartsson, D.F.; Jonasson, J.G.; Sigurdsson, A.; Bergh thorsson, J.T.; He, H.; Bl ondal, T.; Geller, F.; Jakobsdottir, M.; et al. Common variants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European populations. *Nat. Genet.* 2009, 41, 460–464.

30. Świerniak, M.; Wójcicka, A.; Czetwertyńska, M.; Długosinska, J.; Stachlewska, E.; Gierlikowski, W.; Kot, A.; Górnicka, B.; Koperski, L.; Bogdańska, M.; et al. Association between GWAS-Derived rs966423 Genetic Variant and Overall Mortality in Patients with Differentiated Thyroid Cancer. *Clin Cancer Res* 2016, 22, 1111–1119.

31. Wang, Y.-L.; Feng, S.-H.; Guo, S.-C.; Wei, W.-J.; Li, D.-S.; Wang, Y.; Wang, X.; Wang, Z.-Y.; Ma, Y.-Y.; Jin, L.; et al. Confirmation of papillary thyroid cancer susceptibility loci identified by genome-wide association studies of chromosomes 14q13, 9q22, 2q35 and 8p12 in a Chinese population. *J. Med. Genet.* 2013, 50, 689–695.

32. rs966423 (SNP)-Population Genetics-Homo Sapiens Ensembl Genome Browser 98. Available online: https://www.ensembl.org/Homo_sapiens/Variation/Population?r=2:217445117-217446117;v=rs966423;vdb=variation;vf=202626298 (accessed on 14 December 2019).

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).